On 15 October 2014, orphan designation (EU/3/14/1352) was granted by the European Commission to GlaxoSmithKline Trading Services Limited, Ireland, for raxibacumab for the treatment of inhalation anthrax disease.

The sponsorship was transferred to Emergent Countermeasures International Ltd., United Kingdom, in January 2018.

The sponsorship was transferred to Emergent Netherlands B.V., The Netherlands, in April 2019.

Key facts

Active substance
Disease / condition
Treatment of inhalation anthrax disease
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Emergent Netherlands B.V.
Strawinskylaan 411
1077 XX Amsterdam
Tel: +31 20 301 2200

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating